Structure Therapeutics American Stock Performance
| GPCR Stock | 70.07 1.97 2.73% |
Structure Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The entity has a beta of -0.65, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Structure Therapeutics are expected to decrease at a much lower rate. During the bear market, Structure Therapeutics is likely to outperform the market. Use Structure Therapeutics value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Structure Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Structure Therapeutics American are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Even with relatively conflicting fundamental indicators, Structure Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.73) | Five Day Return (6.82) | Year To Date Return 2.86 | Ten Year Return 169.5 | All Time Return 169.5 |
1 | Disposition of 15535 shares by Fmr Llc of Structure Therapeutics subject to Rule 16b-3 | 12/08/2025 |
2 | Structure Therapeutics Reassessing Valuation After Strong Phase 2b Obesity Data for Oral GLP1 Aleniglipron | 12/15/2025 |
3 | H.C. Wainwright Upgrades Structure Therapeutics on Massive Arbitrage Opportunity for Oral GLP-1 | 01/08/2026 |
4 | A 10 percent Owner Of Structure Therapeutics Shed Shares | 01/13/2026 |
5 | Structure Therapeutics Inc. Has Gained Over 130 percent in 3 Months. Here is Why | 01/15/2026 |
6 | Jim Cramer on Structure Therapeutics I Dont Want to Touch It | 01/16/2026 |
7 | Structure Therapeutics Stock Price Expected to Rise, JPMorgan Chase Co. Analyst Says | 01/22/2026 |
8 | This Healthcare Company Believes Its GLP-1 Pill Could Be Next in Line After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. | 02/05/2026 |
9 | FY2030 Earnings Forecast for GPCR Issued By HC Wainwright | 02/13/2026 |
| Begin Period Cash Flow | 129.8 M | |
| Total Cashflows From Investing Activities | -358.9 M |
Structure | Build AI portfolio with Structure Stock |
Structure Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,744 in Structure Therapeutics American on November 16, 2025 and sell it today you would earn a total of 3,263 from holding Structure Therapeutics American or generate 87.15% return on investment over 90 days. Structure Therapeutics American is currently generating 1.6468% in daily expected returns and assumes 13.8545% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Structure, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Structure Therapeutics Target Price Odds to finish over Current Price
The tendency of Structure Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 70.07 | 90 days | 70.07 | about 37.01 |
Based on a normal probability distribution, the odds of Structure Therapeutics to move above the current price in 90 days from now is about 37.01 (This Structure Therapeutics American probability density function shows the probability of Structure Stock to fall within a particular range of prices over 90 days) .
Structure Therapeutics Price Density |
| Price |
Predictive Modules for Structure Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Structure Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Structure Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Structure Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Structure Therapeutics is not an exception. The market had few large corrections towards the Structure Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Structure Therapeutics American, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Structure Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.71 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 20.29 | |
Ir | Information ratio | 0.12 |
Structure Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Structure Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Structure Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Structure Therapeutics is way too risky over 90 days horizon | |
| Structure Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (122.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Structure Therapeutics generates negative cash flow from operations | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: FY2030 Earnings Forecast for GPCR Issued By HC Wainwright |
Structure Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Structure Stock often depends not only on the future outlook of the current and potential Structure Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Structure Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.6 M | |
| Cash And Short Term Investments | 883.5 M |
Structure Therapeutics Fundamentals Growth
Structure Stock prices reflect investors' perceptions of the future prospects and financial health of Structure Therapeutics, and Structure Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Structure Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 4.16 B | ||||
| Shares Outstanding | 70.64 M | ||||
| Price To Book | 6.43 X | ||||
| EBITDA | (157.24 M) | ||||
| Net Income | (122.53 M) | ||||
| Total Debt | 3.86 M | ||||
| Book Value Per Share | 12.69 X | ||||
| Cash Flow From Operations | (116.64 M) | ||||
| Earnings Per Share | (3.66) X | ||||
| Market Capitalization | 4.95 B | ||||
| Total Asset | 903.33 M | ||||
| Retained Earnings | (329.1 M) | ||||
| Working Capital | 855.19 M | ||||
About Structure Therapeutics Performance
Assessing Structure Therapeutics' fundamental ratios provides investors with valuable insights into Structure Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Structure Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.16) | (0.15) |
Things to note about Structure Therapeutics performance evaluation
Checking the ongoing alerts about Structure Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Structure Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Structure Therapeutics is way too risky over 90 days horizon | |
| Structure Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (122.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Structure Therapeutics generates negative cash flow from operations | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: FY2030 Earnings Forecast for GPCR Issued By HC Wainwright |
- Analyzing Structure Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Structure Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Structure Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Structure Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Structure Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Structure Therapeutics' stock. These opinions can provide insight into Structure Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.